Application of volumetric absorptive microsampling for robust, high-throughput mass spectrometric quantification of circulating protein biomarkers
van den Broek et al.
The finding, in our words
Volumetric absorptive microsampling with the Mitra device enables accurate, reproducible quantification of circulating protein biomarkers from a 10 µL finger-prick blood sample, with extraction recovery of 100–111% across haematocrit levels and stable peptide responses after 22 weeks at -80°C. The automated mass spectrometry workflow reproducibly detected 1661 peptides from 423 proteins, correlating with plasma measurements, which supports remote, personalised disease monitoring.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
The study developed and validated a rapid LC-MS/MS method for quantifying cefazolin in capillary whole blood collected via VAMS, plasma, and plasma ultrafiltrate, showing robust performance across matrices and successful application in a pediatric pilot cohort for therapeutic drug monitoring.
A validated LC-MS/MS method for everolimus using Mitra and Capitainer devices found excellent agreement between capillary microsamples and venous whole blood in 33 adult transplant recipients. The results showed high accuracy and negligible haematocrit effects, supporting the use of microsampling for decentralised therapeutic drug monitoring.
A validated offline SPE-LC-MS/MS method using the Mitra microsampling device successfully quantified tacrolimus, cyclosporine A, tryptophan, kynurenine, and creatinine simultaneously. The method met EMA and FDA criteria, showing agreement between capillary and venous sampling, which could facilitate decentralised therapeutic drug monitoring and transplant follow-up through patient self-collection.
An LC-MS/MS assay using volumetric absorptive microsampling achieved 72.5% to 98.9% accuracy and under 8% precision for measuring circulating endocannabinoids and related lipid mediators. However, drying time significantly altered 2-AG and 2-OG concentrations, and marked differences were observed between whole blood and plasma measurements.